Fulcrum Therapeutics Inc. (FULC) Misses Q4 EPS by 1c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q4 EPS of ($0.50), $0.01 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $685 thousand versus the consensus estimate of $1.89 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Nike names former Pfizer CFO David Denton as new finance chief